New putative insights into neprilysin (NEP)-dependent pharmacotherapeutic role of roflumilast in treating COVID-19

Nowadays, coronavirus disease 2019 (COVID-19) represents the most serious inflammatory respiratory disease worldwide. Despite many proposed therapies, no effective medication has yet been approved. Neutrophils appear to be the key mediator for COVID-19-associated inflammatory immunopathologic, throm...

Full description

Saved in:
Bibliographic Details
Published in:European journal of pharmacology 2020-12, Vol.889, p.173615-173615, Article 173615
Main Authors: El Tabaa, Manar Mohammed, El Tabaa, Maram Mohammed
Format: Article
Language:English
Subjects:
Aminopyridines - pharmacology
Aminopyridines - therapeutic use
Benzamides - pharmacology
Benzamides - therapeutic use
cAMP
COVID-19
COVID-19 - drug therapy
Cyclopropanes - pharmacology
Cyclopropanes - therapeutic use
Full Length
Humans
IL-6-Induced endothelial dysfunction
Neprilysin
Neprilysin - drug effects
Neutrophil-mediated inflammation
Pandemics
Roflumilast
SARS-CoV-2
TGF-β1-induced pulmonary fibrosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nowadays, coronavirus disease 2019 (COVID-19) represents the most serious inflammatory respiratory disease worldwide. Despite many proposed therapies, no effective medication has yet been approved. Neutrophils appear to be the key mediator for COVID-19-associated inflammatory immunopathologic, thromboembolic and fibrotic complications. Thus, for any therapeutic agent to be effective, it should greatly block the neutrophilic component of COVID-19. One of the effective therapeutic approaches investigated to reduce neutrophil-associated inflammatory lung diseases with few adverse effects was roflumilast. Being a highly selective phosphodiesterase-4 inhibitors (PDE4i), roflumilast acts by enhancing the level of cyclic adenosine monophosphate (cAMP), that probably potentiates its anti-inflammatory action via increasing neprilysin (NEP) activity. Because activating NEP was previously reported to mitigate several airway inflammatory ailments; this review thoroughly discusses the proposed NEP-based therapeutic properties of roflumilast, which may be of great importance in curing COVID-19. However, further clinical studies are required to confirm this strategy and to evaluate its in vivo preventive and therapeutic efficacy against COVID-19. [Display omitted] •NEP-based actions of roflumilast as a novel option for COVID-19 therapy.•Roflumilast may inhibit inflammatory, coagulopathy and fibrotic cascades.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2020.173615